Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - The company is entering a cycle of accelerated growth, with expectations for better performance in 2026 compared to 2025, and visibility for double-digit growth in the later part of the decade [3]. Group 1: Company Performance - The company had significant outperformance in 2025, which sets a positive tone for future growth [1][3]. - The company is projected to become the largest healthcare company with over $100 billion in sales [3]. Group 2: Future Outlook - There is optimism regarding the growth cycle that the company is initiating, with expectations for continued improvement in performance [3].